NeoGenomics settles DOJ investigation for $9.8 million
NeoGenomics finalized a civil settlement with the U.S. Department of Justice on June 20, 2026, resolving a federal investigation into consulting services the company provided to healthcare providers under its Laboratory Collaboration Initiative program. The company agreed to pay $9,813,260 plus interest at 4.250% per annum from January 16, 2026. The settlement followed a voluntary disclosure to the Office of Inspector General in November 2021 and is neither an admission of liability by the company nor a concession by the United States that its claims are not well founded.
Key facts
- Settlement payment: $9,813,260 plus interest at 4.250% per annum from January 16, 2026
- Prior accrual as of March 31, 2026: $11.2 million
- Self-disclosure to OIG-HHS: November 2021
- Settlement date: June 20, 2026
- Investigation subject: consulting services to healthcare providers for laboratory testing services under Laboratory Collaboration Initiative program
- Neither an admission of liability by the Company nor a concession by the United States that its claims are not well founded
Why it matters
The settlement resolves a federal healthcare compliance investigation that has been pending since the company's voluntary disclosure in November 2021, removing a material contingency from the company's balance sheet at a cost within the previously accrued $11.2 million reserve.
Share
Derived from 8-K filed 2026-07-20. Not investment advice. View the source filing on SEC.gov →